BioLineRx In-Licenses a Novel, Phase II Ready Drug for the Treatment of Leukemia and Other Hematological Cancers Phase II clinical trials are expected to commence in H1 2013. Read More
BioLineRx Announces BKT-140/BL-8040, for the Treatment of Leukemia and Other Types of Hematological Cancer, to be Presented at 2012 ASH Annual Meeting Read More
BioLineRx Enrolls First Patient in Phase 2 Clinical Trial for BKT-140/BL-8040, for Treatment of Leukemia Partial results expected in Q4 2013. Read More
BioLineRx Announces Issuance of United States Patent Covering Use of BKT-140/BL-8040 for Obtaining Stem Cells
BioLineRx's BKT-140/BL-8040 Receives Orphan Drug Designation for Treatment of AML
BioLineRx Reports Publication in Peer Review Journal of Positive Phase 1/2 Results in Stem Cell Mobilization for Multiple Myeloma Results published in Clinical Cancer Research. Additional clinical trial in stem cell mobilization expected to commence in H1 2014.
BioLineRx Presents Positive Preclinical Results of Acute Myeloid Leukemia Treatment at ASH Conference BKT-140/BL-8040 is currently in Phase 2 study in AML patients, with partial results expected this month and final results expected in H2 2014.
BioLineRx Announces Promising Initial Phase 2 Results of Acute Myeloid Leukemia Treatment Initial results for BKT-140/BL-8040 show substantial mobilization of cancer cells and signs of robust cancer cell death (apoptosis).
Biokine Therapeutics Announces Issuance of European Patent covering the composition and use of novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation, and cancer (BKT130 project).
